Mar 11 2018

WHO, Medicines and health products, pharmaceutical classes.#Pharmaceutical #classes

pharmaceutical classes

WHO urges governments to take action

Pharmaceutical classes

Geneva, 28 November 2017: An estimated 1 in 10 medical products circulating in low- and middle-income countries is either substandard or falsified, according to new research from the World Health Organization (WHO). This means that people are taking medicines that fail to treat or prevent disease.

WHO outlines requirements for rapid cholera tests to prevent major outbreaks

Pharmaceutical classes

In order to treat cholera and quickly stem a potential outbreak, it is important to have a rapid and accurate diagnosis, particularly in countries with weak health systems and sanitation, which are the ones most vulnerable to outbreaks of the disease. Rapid diagnostic tests (RDTs) for cholera exist, but recent published evaluations show their accuracy is not optimal.

To that end, WHO has developed a target product profile, describing the type of assays and their key attributes that are needed in the efforts to detect a cholera outbreak. The target product profile can be used in development of a new diagnostic assay as it provides a clear and tangible vision and focus for product development.

WHO prequalifies indoor residual spray for vector control

Pharmaceutical classes

WHO has prequalified SumiShield 50WG as an indoor residual spray intended to kill malaria-carrying mosquitoes. This development provides procurement agencies and countries with a new tool to prevent the transmission of vector-borne diseases like malaria.

New WHO report confirms world is running out of antibiotics

Pharmaceutical classes

A new report launched on 19 September finds that very few antibiotics currently in development address the serious and growing threat of antimicrobial resistance. “Antibacterial agents in clinical development – an analysis of the antibacterial clinical development pipeline, including Mycobacterium tuberculosis” shows that most of the drugs currently in the clinical pipeline are modifications of existing classes of antibiotics and are only short-term solutions. The report found very few potential treatment options for drug-resistant tuberculosis and 12 other classes of priority pathogens identified by WHO.

Written by admin

Leave a Reply

Your email address will not be published. Required fields are marked *